Drug maker Lupin on Friday said a pre-approval and good manufacturing practices (GMP) inspection conducted by USFDA of its active pharmaceutical ingredient (API) manufacturing facility in Visakhapatnam concluded without any observations.

The inspection was conducted from March 6 – 10, 2023

“We are pleased with the successful completion of the inspection at our Vizag facility,” said Nilesh Gupta, managing director of Lupin.

“This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all,” Gupta added.